Neoantigen-driven personalized vaccines for breast cancer: Platforms, nano-delivery systems, and combination strategies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189610
DOI: 10.1016/j.bbcan.2026.189610 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Xiangdong Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic addre…. Hauptthemen laut MEDLINE: Cancer Vaccines, Breast Neoplasms, Precision Medicine, Antigens, Neoplasm. Die Arbeit nennt 221 Literaturangaben. Gefördert von: National Development and Reform Commission, National Health Commission of the People's Republic of China, Hubei Province Natural Science Foundation.
Abstract (Originalsprache)
Breast cancer (BC) is the most common malignancy among women globally. Despite significant advances, therapeutic resistance and tumor recurrence remain major clinical challenges. Personalized cancer vaccines have recently emerged as a promising strategy to induce durable, highly specific anti-tumor immune responses and improve long-term survival. However, challenges persist in neoantigen prediction, vaccine formulation, and practical implementation, which can hinder the overall effectiveness and widespread adoption of these personalized cancer vaccines. Ongoing technological advancements are expected to facilitate the development of more efficient and accessible personalized vaccines for BC. This review systematically summarizes recent progress in personalized BC vaccines, focusing on neoantigen identification, emerging vaccine platforms, nano-delivery systems, and subtype-specific vaccine strategies. It also discusses the pharmacological basis of these vaccines, including immune activation mechanisms, pharmacokinetic influences on efficacy, and mechanisms of vaccine resistance. Furthermore, we explore combination strategies integrating cancer vaccines with immune checkpoint inhibitors (ICIs), radiotherapy, and chemotherapy to overcome the immunosuppressive tumor microenvironment (TME) and enhance therapeutic efficacy. Ultimately, this review provides a comprehensive reference to guide future research and promote the clinical translation of personalized vaccine-based immunotherapies for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: d202582855@hust.edu.cn.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: d202282220@hust.edu.cn.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: tengfeichao@tjh.tjmu.edu.cn.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: liuqingxu@tjh.tjmu.edu.cn.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: lizaabear@tjh.tjmu.edu.cn.
Förderung
- National Development and Reform Commission
- National Health Commission of the People's Republic of China
- Hubei Province Natural Science Foundation
Zitieren
APA
Liu, X., Liu, J., Chao, T., Liu, Q., & Xiong, H. (2026). Neoantigen-driven personalized vaccines for breast cancer: Platforms, nano-delivery systems, and combination strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189610. https://doi.org/10.1016/j.bbcan.2026.189610
Vancouver
Liu X, Liu J, Chao T, Liu Q, Xiong H. Neoantigen-driven personalized vaccines for breast cancer: Platforms, nano-delivery systems, and combination strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189610. doi:10.1016/j.bbcan.2026.189610
BibTeX
@article{Liu2026,
author = {Liu, Xiangdong and Liu, Junxia and Chao, Tengfei and Liu, Qingxu and Xiong, Huihua},
title = {Neoantigen-driven personalized vaccines for breast cancer: Platforms, nano-delivery systems, and combination strategies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189610},
doi = {10.1016/j.bbcan.2026.189610}
}
EUVIMED